Global Kidney Fibrosis Treatment Market - Size and Forecast Analysis, 2021-2035

Chapter 1 Kidney Fibrosis Treatment Market Executive Summary

• 1.1 Kidney Fibrosis Treatment Market Research Scope
• 1.2 Kidney Fibrosis Treatment Market Estimates and Forecast (2021-2035)
• 1.2.1 Global Kidney Fibrosis Treatment Market Value and Growth Rate (2021-2035)
• 1.2.2 Global Kidney Fibrosis Treatment Market Price Trend (2021-2035)
• 1.3 Global Kidney Fibrosis Treatment Market Value Comparison, by Type (2021-2035)
• 1.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors
• 1.3.2 Pirfenidone
• 1.3.3 Renin Inhibitors
• 1.3.4 Angiotensin II Receptor Blockers (ARBs)
• 1.3.5 Vasopeptidase Inhibitors
• 1.4 Global Kidney Fibrosis Treatment Market Value Comparison, by Application (2021-2035)
• 1.4.1 Chronic Kidney Diseases
• 1.4.2 Kidney Cancer Treatment

Chapter 2 Research Methodology

• 2.1 Introduction
• 2.2 Data Capture Sources
• 2.2.1 Primary Sources
• 2.2.2 Secondary Sources
• 2.3 Market Size Estimation
• 2.4 Market Forecast
• 2.5 Assumptions and Limitations

Chapter 3 Market Dynamics

• 3.1 Market Trends
• 3.2 Opportunities and Drivers
• 3.3 Challenges
• 3.4 Market Restraints
• 3.5 Porter's Five Forces Analysis

Chapter 4 Supply Chain Analysis and Marketing Channels

• 4.1 Kidney Fibrosis Treatment Supply Chain Analysis
• 4.2 Marketing Channels
• 4.3 Kidney Fibrosis Treatment Suppliers List
• 4.4 Kidney Fibrosis Treatment Distributors List
• 4.5 Kidney Fibrosis Treatment Customers

Chapter 5 COVID-19 & Russia?Ukraine War Impact Analysis

• 5.1 COVID-19 Impact Analysis on Kidney Fibrosis Treatment Market
• 5.2 Russia-Ukraine War Impact Analysis on Kidney Fibrosis Treatment Market

Chapter 6 Kidney Fibrosis Treatment Market Estimate and Forecast by Region

• 6.1 Global Kidney Fibrosis Treatment Market Value by Region: 2021 VS 2023 VS 2035
• 6.2 Global Kidney Fibrosis Treatment Market Scenario by Region (2021-2023)
• 6.2.1 Global Kidney Fibrosis Treatment Market Value Share by Region (2021-2023)
• 6.3 Global Kidney Fibrosis Treatment Market Forecast by Region (2024-2035)
• 6.3.1 Global Kidney Fibrosis Treatment Market Value Forecast by Region (2024-2035)
• 6.4 Geographic Market Analysis: Market Facts and Figures
• 6.4.1 North America Kidney Fibrosis Treatment Market Estimates and Projections (2021-2035)
• 6.4.2 Europe Kidney Fibrosis Treatment Market Estimates and Projections (2021-2035)
• 6.4.3 Asia Pacific Kidney Fibrosis Treatment Market Estimates and Projections (2021-2035)
• 6.4.4 Latin America Kidney Fibrosis Treatment Market Estimates and Projections (2021-2035)
• 6.4.5 Middle East & Africa Kidney Fibrosis Treatment Market Estimates and Projections (2021-2035)

Chapter 7 Global Kidney Fibrosis Treatment Competition Landscape by Players

• 7.1 Global Top Kidney Fibrosis Treatment Players by Value (2021-2023)
• 7.2 Kidney Fibrosis Treatment Headquarters and Sales Region by Company
• 7.3 Company Recent Developments, Mergers & Acquisitions, and Expansion Plans

Chapter 8 Global Kidney Fibrosis Treatment Market, by Type

• 8.1 Global Kidney Fibrosis Treatment Market Value, by Type (2021-2035)
• 8.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors
• 8.1.2 Pirfenidone
• 8.1.3 Renin Inhibitors
• 8.1.4 Angiotensin II Receptor Blockers (ARBs)
• 8.1.5 Vasopeptidase Inhibitors

Chapter 9 Global Kidney Fibrosis Treatment Market, by Application

• 9.1 Global Kidney Fibrosis Treatment Market Value, by Application (2021-2035)
• 9.1.1 Chronic Kidney Diseases
• 9.1.2 Kidney Cancer Treatment

Chapter 10 North America Kidney Fibrosis Treatment Market

• 10.1 Overview
• 10.2 North America Kidney Fibrosis Treatment Market Value, by Country (2021-2035)
• 10.2.1 U.S.
• 10.2.2 Canada
• 10.2.3 Mexico
• 10.3 North America Kidney Fibrosis Treatment Market Value, by Type (2021-2035)
• 10.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors
• 10.3.2 Pirfenidone
• 10.3.3 Renin Inhibitors
• 10.3.4 Angiotensin II Receptor Blockers (ARBs)
• 10.3.5 Vasopeptidase Inhibitors
• 10.4 North America Kidney Fibrosis Treatment Market Value, by Application (2021-2035)
• 10.4.1 Chronic Kidney Diseases
• 10.4.2 Kidney Cancer Treatment

Chapter 11 Europe Kidney Fibrosis Treatment Market

• 11.1 Overview
• 11.2 Europe Kidney Fibrosis Treatment Market Value, by Country (2021-2035)
• 11.2.1 UK
• 11.2.2 Germany
• 11.2.3 France
• 11.2.4 Spain
• 11.2.5 Italy
• 11.2.6 Russia
• 11.2.7 Rest of Europe
• 11.3 Europe Kidney Fibrosis Treatment Market Value, by Type (2021-2035)
• 11.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors
• 11.3.2 Pirfenidone
• 11.3.3 Renin Inhibitors
• 11.3.4 Angiotensin II Receptor Blockers (ARBs)
• 11.3.5 Vasopeptidase Inhibitors
• 11.4 Europe Kidney Fibrosis Treatment Market Value, by Application (2021-2035)
• 11.4.1 Chronic Kidney Diseases
• 11.4.2 Kidney Cancer Treatment

Chapter 12 Asia Pacific Kidney Fibrosis Treatment Market

• 12.1 Overview
• 12.2 Asia Pacific Kidney Fibrosis Treatment Market Value, by Country (2021-2035)
• 12.2.1 China
• 12.2.2 Japan
• 12.2.3 India
• 12.2.4 South Korea
• 12.2.5 Australia
• 12.2.6 Southeast Asia
• 12.2.7 Rest of Asia Pacific
• 12.3 Asia Pacific Kidney Fibrosis Treatment Market Value, by Type (2021-2035)
• 12.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors
• 12.3.2 Pirfenidone
• 12.3.3 Renin Inhibitors
• 12.3.4 Angiotensin II Receptor Blockers (ARBs)
• 12.3.5 Vasopeptidase Inhibitors
• 12.4 Asia Pacific Kidney Fibrosis Treatment Market Value, by Application (2021-2035)
• 12.4.1 Chronic Kidney Diseases
• 12.4.2 Kidney Cancer Treatment

Chapter 13 Latin America Kidney Fibrosis Treatment Market

• 13.1 Overview
• 13.2 Latin America Kidney Fibrosis Treatment Market Value, by Country (2021-2035)
• 13.2.1 Brazil
• 13.2.2 Argentina
• 13.2.3 Rest of Latin America
• 13.3 Latin America Kidney Fibrosis Treatment Market Value, by Type (2021-2035)
• 13.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors
• 13.3.2 Pirfenidone
• 13.3.3 Renin Inhibitors
• 13.3.4 Angiotensin II Receptor Blockers (ARBs)
• 13.3.5 Vasopeptidase Inhibitors
• 13.4 Latin America Kidney Fibrosis Treatment Market Value, by Application (2021-2035)
• 13.4.1 Chronic Kidney Diseases
• 13.4.2 Kidney Cancer Treatment

Chapter 14 Middle East & Africa Kidney Fibrosis Treatment Market

• 14.1 Overview
• 14.2 Middle East & Africa Kidney Fibrosis Treatment Market Value, by Country (2021-2035)
• 14.2.1 Saudi Arabia
• 14.2.2 UAE
• 14.2.3 South Africa
• 14.2.4 Rest of Middle East & Africa
• 14.3 Middle East & Africa Kidney Fibrosis Treatment Market Value, by Type (2021-2035)
• 14.3.1 Angiotensin Converting Enzyme (ACE) Inhibitors
• 14.3.2 Pirfenidone
• 14.3.3 Renin Inhibitors
• 14.3.4 Angiotensin II Receptor Blockers (ARBs)
• 14.3.5 Vasopeptidase Inhibitors
• 14.4 Middle East & Africa Kidney Fibrosis Treatment Market Value, by Application (2021-2035)
• 14.4.1 Chronic Kidney Diseases
• 14.4.2 Kidney Cancer Treatment

Chapter 15 Company Profiles and Market Share Analysis: (Business Overview, Market Share Analysis, Products/Services Offered, Recent Developments)

• 15.1 Merck & Co(US)
• 15.2 Pfizer Inc(US)
• 15.3 F. Hoffman-La Roche(Switzerland)
• 15.4 InterMune Inc(US)
• 15.5 Galectin Therapeutics(US)
• 15.6 La Jolla Pharmaceutical Company(US)
• 15.7 ProMetic Life-Sciences Inc(Canada)
• 15.8 BioLine Rx(Israel)
• 15.9 Genzyme Corporation(US)